Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07039929 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07039929 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 24 participants.
The verdict
NCT07039929, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will be conducted to assess the safety, tolerability, and pharmacokinetics of INCB000631 when administered orally to healthy adult participants.
Interventions
- DRUG Placebo
- DRUG INCB000631
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2025-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07039929
The ClinicalTrials.gov registry entry for NCT07039929 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07039929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07039929 about?
NCT07039929 is a clinical study titled "Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants". This study will be conducted to assess the safety, tolerability, and pharmacokinetics of INCB000631 when administered orally to healthy adult participants.
What is the current status of trial NCT07039929?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-07-28. Estimated completion is 2025-10-11.
What interventions are being tested in trial NCT07039929?
The interventions under investigation include: Placebo (DRUG), INCB000631 (DRUG).
Who is sponsoring clinical trial NCT07039929?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.